全文获取类型
收费全文 | 2102篇 |
免费 | 0篇 |
国内免费 | 1篇 |
专业分类
化学工业 | 2篇 |
建筑科学 | 2篇 |
轻工业 | 13篇 |
无线电 | 3篇 |
一般工业技术 | 4篇 |
冶金工业 | 2070篇 |
自动化技术 | 9篇 |
出版年
2022年 | 1篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2019年 | 4篇 |
2014年 | 2篇 |
2013年 | 3篇 |
2011年 | 3篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2005年 | 1篇 |
2004年 | 1篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 2篇 |
1999年 | 73篇 |
1998年 | 686篇 |
1997年 | 396篇 |
1996年 | 245篇 |
1995年 | 137篇 |
1994年 | 109篇 |
1993年 | 125篇 |
1992年 | 16篇 |
1991年 | 19篇 |
1990年 | 15篇 |
1989年 | 18篇 |
1988年 | 24篇 |
1987年 | 18篇 |
1986年 | 10篇 |
1985年 | 12篇 |
1983年 | 3篇 |
1982年 | 12篇 |
1981年 | 7篇 |
1980年 | 12篇 |
1978年 | 4篇 |
1977年 | 40篇 |
1976年 | 89篇 |
1975年 | 2篇 |
1955年 | 1篇 |
排序方式: 共有2103条查询结果,搜索用时 15 毫秒
931.
932.
933.
934.
935.
The study aim was to investigate the role of the parasympathetic nervous system in the control of glucose tolerance in man. Glucose kinetics were determined during an oral glucose tolerance test (OGTT) in six subjects with truncal vagotomies and six control subjects. Basal plasma glucose levels in the two groups were equal; however, 20 to 40 minutes after the OGTT, glucose was higher in vagotomized compared with control subjects (P < .02). There were no differences in insulin levels between the subjects. Glucagon decreased after the OGTT in the controls, whereas in the vagotomized subjects it increased transiently and did not decrease beyond basal levels. There was no difference in basal hepatic glucose production, but suppression was greater in controls in the first 10 minutes (P < .01). Gut-derived glucose appearance increased faster and to a higher level (56.0 +/- 8 v 29.7 +/- 2.9 mumol/kg/min, P < .02) in vagotomized subjects. There were no differences in the metabolic clearance rate of glucose between the two groups. It is concluded that parasympathetic innervation of the pancreas is essential for suppression of glucagon secretion during hyperglycemia. However, abnormal glucose tolerance in vagotomized subjects is primarily due to rapid gut glucose absorption, with the denervated parasympathetic system playing only a minor role. 相似文献
936.
JD Hainsworth SE Jones RG Mennel JL Blum FA Greco 《Canadian Metallurgical Quarterly》1996,14(5):1611-1616
PURPOSE: Paclitaxel is a highly active single agent in the treatment of breast cancer. However, its optimal incorporation into combination regimens awaits definition. In this phase II study, we added paclitaxel, administered by 1-hour infusion, to a previously described combination regimen that included mitoxantrone, fluorouracil (5-FU), and high-dose leucovorin (NFL). PATIENTS AND METHODS: Forty-six patients with metastatic breast cancer received the following regimen as first- or second-line treatment: paclitaxel 135 mg/m2 by 1-hour intravenous (i.v.) infusion on day 1, mitoxantrone 10 mg/m2 by i.v. bolus on day 1, 5-FU 350 mg2/m by i.v. bolus on days 1, 2, and 3, and leucovorin 300 mg i.v. over 30 to 60 minutes immediately preceding 5-FU on days 1, 2, and 3. Courses were administered at 3-week intervals for a total of eight courses in responding patients. RESULTS: Twenty-three of 45 assessable patients (51%) had major responses. Previous chemotherapy, and in particular previous treatment with doxorubicin, did not affect response rate. The median response duration was 7.5 months. Myelosuppression was moderately severe, with 76% of courses resulting in grade 3 or 4 leukopenia. Hospitalization for treatment of fever during neutropenia was required in 13% of courses, and two patients died as a result of sepsis. Two patients developed severe congestive heart failure after a large cumulative anthracycline dose. CONCLUSION: This combination regimen was active as first- or second-line therapy for metastatic breast cancer, although its activity compared with other combination regimens or with paclitaxel alone is unclear. Myelosuppression was more severe than anticipated based on previous results with the NFL regimen or with paclitaxel administered at this dose and schedule as a single agent. The infrequent development of cardiotoxicity in these patients suggests that the paclitaxel/mitoxantrone combination may not share the problems previously reported with the paclitaxel/doxorubicin combination. 相似文献
937.
938.
939.
940.